Edwards Lifesciences Corp

Edwards Lifesciences Corp (EW) - Projecting 2021 Global Sales of $4.9-5.3 Billion; Underlying Growth in Mid-teens.
Projecting 2021 Tavr Sales of $3.2-3.6 Billion; Underlying Growth 15-20%.
Estimating 2021 Adjusted Earnings per Share $2.00-2.20.
Edwards Lifesciences - Initial Clinical Experience With Next-generation Pascal Delivery System Expected in 2021.
Edwards Lifesciences - Initial Clinical Experience With Next-generation Evoque Mitral System Expected in 2021.
U.S. Approval for Pascal Dmr Expected in Late 2022.
Evoque Tricuspid European Approval Expected in 2022.
Looks Forward to Launch of Inspiris Resilia in China in 2021.
Edwards Lifesciences - in 2021, Will Also Be Enrolling Patients in Restore Pivotal Trial for U.S. Approval of Harpoon.
Edwards Lifesciences - in 2021, Expects to Launch New Surgical Mitral Valve, Mitris Resilia, in U.S. and Japan.
Edwards Lifesciences - Anticipates Launch of Viewfinder Connectivity Solution in 2021.
FY2021 Earnings per Share View $2.23, Revenue View $5.10 Billion -- Refinitiv Ibes Data (analyst estimates).